Non-Invasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker

Completed

Conditions studied: Down Syndrome (Trisomy 21), Edwards Syndrome (Trisomy 18), Patau Syndrome (Trisomy 13), Turner Syndrome

In brief

Validate that circulating cell free fetal nucleic acid can be used to identify a direct marker for fetal aneuploidy, particularly fetal Down Syndrome (DS), that is better than surrogate markers.

Key facts

Study ID

NCT00770458

Run by

Sequenom, Inc.

People needed

1000

Starts

2008-06-01

Expected to finish

2009-12-01

Last updated by the study team

2010-01-06

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Subject is female
• Subject is pregnant
• Subject is high risk aneuploid patient undergoing genetic counseling, unltrasound screening, amniocentesis and/or CVS procedure
• Subject is willing to provide blood specimen

You may not qualify if…

• Subject is not pregnant
• Subject is not willing to provide blood specimen
• Subject is not haveing aneuploid screening

Where it is running

• UCSD Fetal Care & Genetics Center — La Jolla, California, United States
• San Diego Perinatal Center — San Diego, California, United States
• Obstetrix Medical Group of San Jose — San Jose, California, United States
• Obstetrix Medical Group of Colorado — Denver, Colorado, United States
• Women & Infants — Providence, Rhode Island, United States
• A.R.U.P. — Salt Lake City, Utah, United States
• Obstetrix Medical Group of Washington — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.